The arduous track leading to the medical degree generally continues along a single path toward equally taxing residencies and fellowships. What usually follows is a lifetime of comforting and healing in private, public, or academic settings. Few professions can claim… Read More ›
As I and others have cautioned, there has been an excess of exuberance about the recent slowdown in health care spending. The jury on that is still out on the degree to which the encouraging numbers are due to profound… Read More ›
The release this past week of the Medicare Trustees’ report was met with widespread enthusiasm among health economists and supporters of the federal health reforms in the Affordable Care Act (ACA). The report confirmed that Medicare costs continue to exceed… Read More ›
Last August, I wrote a JAMA Forum post about the slowdown in health care spending and speculated about whether the slow growth is likely to continue. The release of 3 new studies on this issue enables us to revisit the… Read More ›
Media coverage of new public health regulations often seems to follow a template: The [regulatory agency]’s plan to implement [public health regulation] is causing controversy among [businesses affected] and [individuals who object]. While public health officials say the plan is… Read More ›
Dr Robert Potenza and Dominica Potenza, partners in life and in work, are, respectively, a cardiologist and a registered nurse who have a cardiology/internal medicine practice in the Bronx. (Dominica, who is pursuing a Doctorate of Nursing Practice at Hunter… Read More ›
President Obama spoke extensively about implementation of the Affordable Care Act (ACA) during his recent press conference, particularly about what it means for people: So there are a whole host of benefits that, for the average American out there, for… Read More ›
On April 1, India’s Supreme Court ruled against drug company Novartis regarding its claim for a patent on the lucrative and widely used cancer drug imatinib (marketed by Novartis as Gleevec in the United States and as Glivec elsewhere). To… Read More ›
There are few minutiae of health care economics that policy wonks love to fight about more than insurers’ administrative costs. These are costs for things like management and marketing that are not directly related to care delivery. Are they too… Read More ›
“The rich are different from you and me. They have more money,” a cynic once noted. The modern-day version would add a deeply troubling observation: and they live longer too. The gap in life expectancy between the better off and… Read More ›
